small-cap

The long-awaited rotation into small-cap stocks may be losing steam again as Citigroup doubles down on large-cap U.S. equities, arguing that artificial intelligence-led earnings growth continues to outweigh concerns about slowing economic momentum and elevated interest rates. That could have...

The stock market is caught in a violent tug-of-war between speculative futures and physical supply-chain realities. Just before late Tuesday’s sudden ceasefire announcement triggered a massive relief rally, live trading data revealed a market bracing for a severe, sustained stagflationary...

As geopolitical tensions in Iran and stagflation fears drag broader U.S. markets into the red, small-cap stocks are showing surprising resilience, leaving market experts sharply divided on what comes next. A Striking Market Divergence Despite the specter of war and rising crude oil prices, the...

Louis Navellier, the growth investor behind Navellier & Associates, joined Benzinga’s PreMarket Playbook Thursday morning to discuss American exceptionalism in equity pricing, growth stocks and economic indicators impacting the markets. International Stocks: Navellier says he doesn...

Small-cap stocks could see a significant boost under President-elect Donald Trump’s presidency, potentially doubling their value over the next two years, according to Tom Lee, head of research at Fundstrat. What Happened: During an interview with CNBC on Friday, Wall Street strategist Lee...

Small-cap equities could be the dark horse of the next 10 years after the previous decade saw an outsized return from the U.S. large-cap sector. The latest Vanguard market perspective highlights the U.S. small-cap sector as the leading domestic opportunity, projecting an annualized return between 5...

Small-cap stocks have underperformed their mid- and large-cap counterparts in the broader market recovery seen since late October. Underwhelming Show: The S&P 600 and the Russell 2,000 Indices, which comprise small-cap stocks, are barely in the green even as the major averages are solidly...

One of 2017's better performers has been the biotech sector, which turned around after a disappointing 2016.  Biotech stocks fell steeply early in the year in 2016, weighed down by fears of price control and clampdowns on price gouging. Subsequently, the sector traded in a broad range...